Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Kinnate Biopharma Inc (KNTE)

Kinnate Biopharma Inc (KNTE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories Newswire.ca - Fri Mar 1, 7:35AM CST

Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program...

KNTE : 2.65 (-0.38%)
Wall Street - shutterstock_1321462394
S&P Futures Plunge Ahead of FOMC Meeting, Oil’s Climb Raises Inflation Concerns Barchart - Tue Sep 19, 2023

December S&P 500 futures (ESZ23) are trending down -0.51% this morning as market participants geared up for a big week for central banks, with the spotlight on the Federal Reserve’s interest rate decision...

ESZ23 : 4,694.27s (-0.58%)
AAPL : 228.52 (-0.21%)
AYX : 48.26 (+0.02%)
TSLA : 339.64 (-0.70%)
ARM : 133.14 (-0.42%)
KGF.LN : 289.300 (+1.54%)
NIO : 4.70 (+1.08%)
DELL : 138.92 (+3.70%)
AVGR : 0.7890 (+4.61%)
KNTE : 2.65 (-0.38%)
GMED : 84.91 (+1.58%)
PLNT : 100.02 (+1.77%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029 FinancialNewsMedia - Thu Jun 1, 2023

EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END

KTTA : 3.18 (-0.31%)
DAWN : 13.34 (-2.06%)
SWTX : 36.30 (-3.04%)
VSTM : 3.93 (+3.69%)
KNTE : 2.65 (-0.38%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029 PR Newswire - Thu Jun 1, 2023

/PRNewswire/ -- Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue....

KTTA : 3.18 (-0.31%)
SWTX : 36.30 (-3.04%)
DAWN : 13.34 (-2.06%)
VSTM : 3.93 (+3.69%)
KNTE : 2.65 (-0.38%)
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences Globe Newswire - Wed Jun 1, 2022

SAN FRANCISCO and SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology...

KNTE : 2.65 (-0.38%)
Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022 Globe Newswire - Thu May 26, 2022

Preclinical data from a study of the Company’s pan-RAF product candidate, KIN-2787, in combination with MEK inhibitor, also accepted for publication in the...

KNTE : 2.65 (-0.38%)
Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidate, KIN-3248 Globe Newswire - Mon Apr 18, 2022

SAN FRANCISCO and SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on...

KNTE : 2.65 (-0.38%)
Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting Globe Newswire - Fri Apr 8, 2022

Three poster presentations highlight the unmet need for targeted therapies in BRAF and/or NRAS-altered cancers, including non-small cell lung cancer and...

KNTE : 2.65 (-0.38%)
Kinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational Updates Globe Newswire - Mon Mar 28, 2022

Initiated Phase 1 clinical trial for KIN-3248 in the first quarter of 2022 Initial monotherapy data from the ongoing KN-8701 Phase 1 trial expected in the...

KNTE : 2.65 (-0.38%)
Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation at the American Association for Cancer Research Annual Meeting Globe Newswire - Tue Mar 8, 2022

Poster presentations to highlight data from ongoing studies of the company’s lead Pan-RAF kinase inhibitor program, KIN-2787...

KNTE : 2.65 (-0.38%)

Barchart Exclusives

Up 882% YTD, Is It Too Late to Buy This Fintech Stock? Barchart - 7 minutes ago
A recent guidance boost from DAVE propelled the stock even higher. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot